Table 1 Baseline characteristics of patients according to FT3 calssification
Variable | LT3S group (n = 168) | non-LT3S group (n = 426) | P value |
|---|---|---|---|
Age, year | 61 ± 16 | 57 ± 15 | 0.009 |
Male, n (%) | 114 (67.9) | 300 (70.4) | 0.540 |
History, n (%) | |||
Hypertension | 80(47.6) | 189(44.4) | 0.473 |
Diabetes mellitus | 44(26.2) | 88(20.7) | 0.144 |
Ischemic heart disease | 58(34.5) | 142(33.3) | 0.782 |
Dilated cardiomyopathy | 38(22.6) | 118(27.7) | 0.205 |
Valvular heart disease | 47(28.0) | 98(23.0) | 0.204 |
Atrial fibrillation | 82(49.1) | 134(32.2) | < 0.001 |
Physical examination | |||
Heart rate, beats/min | 79 ± 19 | 79 ± 16 | 0.999 |
Systolic blood pressure, mmHg | 112 ± 19 | 117 ± 19 | 0.003 |
Body mass index, kg/m2 | 23.0 ± 4.3 | 24.0 ± 4.7 | 0.016 |
NYHA functional class, n (%) | < 0.001 | ||
II | 11(6.5) | 86(20.2) | |
III | 68(40.5) | 204(47.9) | |
IV | 89(53.0) | 136(31.9) | |
LVEF (%) | 41.6 ± 14.1 | 39.6 ± 14.5 | 0.128 |
LVEF < 40 %, n (%) | 82(48.8) | 235(55.2) | 0.162 |
LVEDD, mm | 60.0 ± 13.2 | 62.5 ± 12.8 | 0.031 |
Laboratory results | |||
Hemoglobin, g/dL | 126.1 ± 26.4 | 138.5 ± 20.8 | < 0.001 |
Sodium, mmol/L | 138.2 ± 4.2 | 139.6 ± 3.3 | < 0.001 |
Albumin, g/dL | 37.4 ± 4.8 | 40.5 ± 4.4 | < 0.001 |
Blood urea nitrogen, mmol/L | 11.5 ± 6.5 | 8.4 ± 3.9 | < 0.001 |
Creatinine, umol/L | 117.1 ± 57.7 | 96.8 ± 36.3 | < 0.001 |
NT-proBNP, pg/mL | 3165(1441–5525) | 1756(998–3263) | < 0.001 |
Medication on presentation, n (%) | |||
Diuretics | 134(79.8) | 330(77.5) | 0.542 |
ACEI/ARB/ARNI | 99(58.9) | 236(55.4) | 0.435 |
β-blockers | 132(78.6) | 328(77.0) | 0.679 |
Spironolactone | 106(63.1) | 262(61.5) | 0.719 |
Intravenous cardiotonic therapy | |||
Dopamine | 121(72.0) | 191(44.8) | < 0.001 |
Dobutamine | 5(3.0) | 13(3.1) | 0.961 |
Norepinephrine | 7(4.2) | 16(3.8) | 0.815 |
In-hospital death, n (%) | 15(8.9) | 12(2.8) | 0.001 |
One-year all cause death, n (%)a | 53(34.6) | 47(11.3) | < 0.001 |